Key facts
- This page summarizes Faisal Ghiath Sukhtian's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Jul 2026, 15:19.
Faisal Ghiath Sukhtian - 29 Jul 2026 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)
- Reporting relationship
- Director
- Issuer ticker
- OTLK
- Reported as of
- 29 Jul 2026
- Net transaction value
- +$99,996
- SEC form
- 4
- Accepted by SEC
- 29 Jul 2026, 15:19:37 UTC
- Prior SEC filing
- 27 May 2026
- Source filing
- View source filing
- Reporting owner signature
- Lawrence Kenyon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Faisal Ghiath Sukhtian filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 29 Jul 2026.
Change
- Previous filing in this sequence was filed on 27 May 2026.
- Current net transaction value: +$99,996.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001716033
Primary reporting owner
Sukhtian Faisal Ghiath
- Relationship
- Director
- Address
- C/O OUTLOOK THERAPEUTICS, INC., 111 S. WOOD AVE, UNIT #100, ISELIN
- Signature
- Lawrence Kenyon, Attorney-in-Fact
- Signature date
- 29 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OTLK
transaction
Common Stock
Purchase
- Transaction value
- $99,996
- Shares
- +95,398
- Change %
- +76%
- Price
- $1.05
- Shares after
- 220,972
- Date
- 29 Jul 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.